News

CUREator+ Dementia & Cognitive Decline Incubator

Posted: 2 July 2024 The CUREator+ Dementia and Cognitive Decline incubator program, a partnership between Brandon BioCatalyst, ANDHealth and Dementia Australia, has opened its first funding round. Companies pioneering innovative health technologies to enhance the lives of individuals…

BioMelbourne Network Board strengthened with five new appointments

Posted: 1 July 2024 BioMelbourne Network, the peak body in the Victorian healthtech industry, is pleased to announce the appointment of five new Directors and Treasurer to its Board, effective from 1 July 2024. These appointments refill the…

GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer

Posted: 27 June 2024 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has released its novel Comprehensive Risk Assessment…

Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer

Posted: 27 June 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces topline results from the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial…

INOVIQ isolates brain-derived exosomes in Alzheimer’s

Posted: 27 June 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that its NEURO-NET™ technology can isolate brain-derived exosomes in Alzheimer’s Disease. NEURO-NET captures exosomes secreted from various brain cells. Exosomes provide a “fingerprint” of the…

Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging

Posted: 27 June 2024 Telix today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET1 agent, TLX250-CDx (Zircaix®2, 89Zr-DFO-girentuximab), for the…

MCRI and Incepta Pharmaceuticals partner to protect children from rotavirus

Posted: 27 June 2024 Murdoch Children’s Research Institute (MCRI) and Incepta Pharmaceuticals, based in Bangladesh, have embarked on a collaboration aimed at bringing life-saving innovation to the global healthcare landscape. MCRI has announced the signing of a non-exclusive licensing…

Stem cell medicine advancements showcased at reNEW’s scientific meeting

Posted: 27 June 2024 Emerging treatments for muscle, kidney and heart diseases were among the stem cell projects showcased at the Annual Scientific Meeting of the Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW) in Melbourne. reNEW is…

Optiscan soars on new InVue imaging device for precision surgery

Posted: 27 June 2024 Optiscan is excited to be included in Stockhead regarding the unveiling of InVue™ – our next gen microscopic medical imaging device for precision surgery. The article focuses on how InVue™ broadens Optiscan’s product portfolio in the surgical…

MTPConnect strengthens life science links with US through MoU with Biocom California at the 2024 BIO Convention

Posted: 27 June 2024 MTPConnect, Australia’s life sciences innovation accelerator, and Biocom California have committed to working closely together to support the growth of life sciences companies, with the signing today of a Memorandum of Understanding at the 2024…

MTPConnect Workforce Initiative Delivers Skills Needed to Power Life Sciences Sector Growth

Posted: 27 June 2024 Over the last three and a half years, REDI has delivered training, mentoring and industry placements to more than 8,400 participants across Australia, nearly double the original target. The report – ‘Improving workforce skills in…

Brandon Capital Announces Sixth Fund with A$270 million (US$180 million) Initial Close to Drive Life Science Innovation

Posted: 27 June 2024 Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the launch of its sixth fund, Brandon Capital Fund VI, with an initial close at A$270 million (US$180 million). This new fund will…

Home

News & opinion

Member Directory

Events